Two new senior hires announced within the Healthcare & Life Sciences team; Dr Tom Burt, as Assistant Director in the corporate team and Catherine Isted as Specialist Sales.
Both will work alongside James Steel, Corporate-Head of Healthcare & Life Sciences, and Oliver Jackson, Corporate Associate, who together advised on the $100m Series C fund raising for CeQur SA, the insulin infusion business, earlier this month; the second largest European med-tech private placement in history.
Dr Tom Burt has joined Peel Hunt from Ares Life Sciences where he worked as an Investment Manager. Prior to this he was an associate at Novo A/S in Denmark and at Piper Jaffray’s European Healthcare Investment Banking division, where he was responsible for transaction management, investment oversight and valuation analysis for both equity capital markets and M&A mandates. Previously Tom worked at GlaxoSmithKline for four years as a research engineer while completing his doctorate in Biochemical Engineering & Bioprocess Leadership.
Catherine Isted, who will officially begin her new role later this month, has a first class honours degree in Chemistry and started her career with Merck Sharp & Dohme in the UK and most recently worked at Nomura Code where she spent nine years working in healthcare specialist sales. Previously, she worked at ABN AMRO, where she was #1 ranked in biotechnology specialist sales and #3 ranked in med tech specialist sales, and at Morgan Stanley as a healthcare and life sciences analyst. Catherine brings extensive sector knowledge to the role as well as significant experience working with many of the largest institutions across Europe and the UK.
